PriceTargets.com logo

Marinus Pharmaceuticals - MRNS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $8.83
  • Forecasted Upside: 396.25%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$1.78 As of 10/4/2024 06:19 PM ET
▲ +0.05 (2.89%)

This chart shows the closing price for MRNS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Marinus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRNS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNS

Analyst Price Target is $8.83
▲ +396.25% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Marinus Pharmaceuticals in the last 3 months. The average price target is $8.83, with a high forecast of $13.00 and a low forecast of $3.00. The average price target represents a 396.25% upside from the last price of $1.78.

This chart shows the closing price for MRNS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 investment analysts is to moderate buy stock in Marinus Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/13/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/12/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/30/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
9/24/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$13.00 ➝ $13.00
9/23/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$10.00 ➝ $10.00
9/23/2024OppenheimerUpgradeMarket Perform ➝ Outperform$6.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$13.00 ➝ $13.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$13.00 ➝ $13.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
8/14/2024LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
6/18/2024Truist FinancialReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/7/2024HC WainwrightLower TargetBuy ➝ Buy$27.00 ➝ $11.00
4/17/2024Truist FinancialLower TargetBuy ➝ Buy$25.00 ➝ $10.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
4/16/2024Robert W. BairdReiterated RatingOutperform ➝ Neutral
4/15/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$24.00 ➝ $3.00
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$28.00
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
3/7/2024OppenheimerReiterated RatingMarket Perform ➝ Market Perform$9.00
3/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$24.00
3/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00
12/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
11/8/2023Truist FinancialLower TargetBuy ➝ Buy$32.00 ➝ $25.00
9/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$28.00
9/20/2023LADENBURG THALM/SH SHBoost Target$13.00 ➝ $15.50
9/20/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$20.00 ➝ $21.00
9/20/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
8/11/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$21.00 ➝ $20.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$27.00
8/11/2023Truist FinancialLower TargetBuy ➝ Buy$42.00 ➝ $32.00
8/11/2023LADENBURG THALM/SH SHLower TargetBuy ➝ Buy$17.00 ➝ $13.00
8/11/2023OppenheimerDowngradeOutperform ➝ Market Perform$14.00 ➝ $9.00
8/11/2023Robert W. BairdLower TargetOutperform ➝ Outperform$24.00 ➝ $20.00
5/12/2023Truist FinancialLower Target$50.00 ➝ $42.00
3/8/2023HC WainwrightReiterated RatingBuy$27.00
3/8/2023JMP SecuritiesLower TargetMarket Outperform$19.00 ➝ $18.00
3/8/2023Royal Bank of CanadaLower TargetOutperform$23.00 ➝ $22.00
3/8/2023Cantor FitzgeraldReiterated RatingOverweight$28.00
1/23/2023Leerink PartnersLower TargetOutperform$27.00 ➝ $23.00
1/20/2023Royal Bank of CanadaInitiated CoverageOutperform$23.00
1/6/2023HC WainwrightReiterated RatingBuy$27.00
11/9/2022Robert W. BairdLower TargetOutperform$32.00 ➝ $24.00
11/9/2022HC WainwrightLower Target$38.00 ➝ $27.00
6/9/2022JMP SecuritiesReiterated RatingBuy$22.00
5/16/2022OppenheimerLower TargetNA$28.00
4/20/2022Cantor FitzgeraldBoost Target$25.00 ➝ $28.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/22/2022HC WainwrightReiterated RatingBuy$38.00
3/22/2022Leerink PartnersLower TargetOutperform$30.00 ➝ $27.00
3/22/2022JMP SecuritiesBoost TargetMarket Outperform$21.00 ➝ $22.00
3/22/2022Truist FinancialBoost TargetBuy$35.00 ➝ $50.00
2/23/2022Truist FinancialLower Target$40.00 ➝ $35.00
12/20/2021Leerink PartnersLower TargetOutperform$32.00 ➝ $30.00
12/7/2021JMP SecuritiesReiterated RatingBuy$23.00
10/18/2021Leerink PartnersReiterated RatingOutperform
10/5/2021JMP SecuritiesReiterated RatingBuy$23.00
9/20/2021JMP SecuritiesReiterated RatingBuy$23.00
8/30/2021JMP SecuritiesReiterated RatingBuy$23.00
8/19/2021Robert W. BairdReiterated RatingBuy$32.00
8/19/2021Leerink PartnersReiterated RatingBuy
8/18/2021Truist FinancialBoost TargetBuy$35.00 ➝ $40.00
8/17/2021Cantor FitzgeraldReiterated RatingOverweight
5/20/2021Robert W. BairdReiterated RatingBuy$32.00
3/10/2021HC WainwrightBoost TargetBuy$35.00 ➝ $38.00
11/10/2020Cantor FitzgeraldBoost TargetOverweight$8.00 ➝ $27.00
9/30/2020Truist FinancialInitiated CoverageBuy$35.00
9/28/2020HC WainwrightBoost TargetBuy$9.00 ➝ $35.00
9/25/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00
9/25/2020JMP SecuritiesBoost TargetPositive ➝ Outperform$7.00 ➝ $26.00
9/23/2020OppenheimerBoost TargetOutperform$7.00 ➝ $28.00
9/15/2020JMP SecuritiesBoost Target$28.00 ➝ $16.00
9/15/2020OppenheimerBoost TargetPositive ➝ Outperform$24.00 ➝ $28.00
9/15/2020Leerink PartnersBoost TargetOutperform$24.00 ➝ $32.00
9/15/2020HC WainwrightReiterated RatingBuy$36.00
9/15/2020Cantor FitzgeraldBoost TargetOverweight$24.00 ➝ $32.00
9/15/2020Jefferies Financial GroupBoost TargetBuy$16.00 ➝ $24.00
9/8/2020OppenheimerReiterated RatingBuy$24.00
8/7/2020OppenheimerReiterated RatingBuy$24.00
8/6/2020LADENBURG THALM/SH SHReiterated RatingBuy$18.00
7/1/2020CowenInitiated CoverageOutperform
6/30/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $36.00
5/5/2020Cantor FitzgeraldLower TargetOverweight$28.00 ➝ $24.00
5/5/2020HC WainwrightReiterated RatingBuy$24.00
4/9/2020Craig HallumInitiated CoverageBuy$18.00
4/1/2020LADENBURG THALM/SH SHReiterated RatingBuy$20.00
1/10/2020HC WainwrightBoost TargetBuy$20.00 ➝ $24.00
12/19/2019OppenheimerInitiated CoverageOutperform$24.00
11/18/2019LADENBURG THALM/SH SHReiterated RatingBuy$20.00
11/13/2019HC WainwrightReiterated RatingBuy$20.00
10/18/2019HC WainwrightSet TargetBuy$20.00
10/18/2019Cantor FitzgeraldReiterated RatingOverweight$28.00
(Data available from 10/4/2019 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/8/2024
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/7/2024
  • 6 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
5/7/2024
  • 2 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 1 very positive mentions
  • 56 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 6 very positive mentions
  • 64 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 5 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/4/2024
  • 6 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024

Current Sentiment

  • 6 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Marinus Pharmaceuticals logo
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.
Read More

Today's Range

Now: $1.78
Low: $1.71
High: $1.82

50 Day Range

MA: $1.43
Low: $1.10
High: $1.90

52 Week Range

Now: $1.78
Low: $1.05
High: $11.26

Volume

344,570 shs

Average Volume

1,116,700 shs

Market Capitalization

$97.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Marinus Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on Marinus Pharmaceuticals in the last year: Cantor Fitzgerald, EF Hutton Acquisition Co. I, HC Wainwright, JMP Securities, LADENBURG THALM/SH SH, Oppenheimer Holdings Inc., Robert W. Baird, Royal Bank of Canada, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for MRNS.

What is the current price target for Marinus Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Marinus Pharmaceuticals in the last year. Their average twelve-month price target is $8.83, suggesting a possible upside of 396.3%. Cantor Fitzgerald has the highest price target set, predicting MRNS will reach $13.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $3.00 for Marinus Pharmaceuticals in the next year.
View the latest price targets for MRNS.

What is the current consensus analyst rating for Marinus Pharmaceuticals?

Marinus Pharmaceuticals currently has 3 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MRNS.

What other companies compete with Marinus Pharmaceuticals?

Other companies that are similar to Marinus Pharmaceuticals include Puma Biotechnology, RAPT Therapeutics, Cryoport, Taysha Gene Therapies and Lyell Immunopharma. Learn More about companies similar to Marinus Pharmaceuticals.

How do I contact Marinus Pharmaceuticals' investor relations team?

Marinus Pharmaceuticals' physical mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company's listed phone number is (484) 801-4670 and its investor relations email address is [email protected]. The official website for Marinus Pharmaceuticals is www.marinuspharma.com. Learn More about contacing Marinus Pharmaceuticals investor relations.